MedTrace Logo

Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN

NCT04939480 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-04-25

No results posted yet for this study

Summary

Targeting the PD-L1 pathway with atezolizumab has demonstrated objective responses across a broad range of malignancies including head and neck squamous cell carcinoma (SCCHN). MO39839 is a window of opportunity study investigating the feasibility, safety and postoperative complication rates of preoperative short time immunotherapy with atezolizumab in patients with local SCCHN. In the scope of MO39839 a comprehensive translational research program will be conducted to assess the potential effect of atezolizumab on dynamics in tumor immunity, and to identify and validate potential predictive and prognostic biomarkers.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg intravenous solution

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Stefan Kasper-Virchow, Prof. Dr. · University Hospital, Essen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2024-03-14
Completion
2024-03-14

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04939480 on ClinicalTrials.gov